JURA Bio
JURA Bio is pioneering AI-native drug discovery by bridging the gap between computational design and physical reality in biological AI. Their mission is to revolutionize the discovery and development of safe and effective drugs, making even the hardest therapeutic targets tractable. By leveraging manufacturing-aware generative models, JURA Bio not only designs new therapeutics but also builds, tests, and learns from them at unprecedented scale. Their approach integrates machine learning, synthetic biology, and high-throughput experimentation to create a new paradigm in drug discovery, where AI learns from tens of billions of real protein interactions and every candidate is inherently human-safe.
Industries
Nr. of Employees
small (1-50)
Patents
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2025-09-23 • US-12421293-B2
View DetailsMajor histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2023-11-28 • US-11826385-B2
View Details
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2025-09-23 • US-12421293-B2
View DetailsMajor histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
2023-11-28 • US-11826385-B2
View DetailsProducts
Synthesized human antibody and TCR candidate libraries
Large, in-distribution libraries of human-like antibody CDRs and TCR candidates generated by manufacturing-aware models and physically synthesized for screening.
Synthesized human antibody and TCR candidate libraries
Large, in-distribution libraries of human-like antibody CDRs and TCR candidates generated by manufacturing-aware models and physically synthesized for screening.
Expertise Areas
- Generative protein and sequence design
- High-throughput DNA library synthesis and manufacture
- High-throughput functional screening in human cells
- Sequence-to-activity predictive modeling (CNNs, transformers)
Key Technologies
- Manufacturing-aware generative models
- High-throughput DNA synthesis
- Single-cell sequencing
- DNA-barcoded antigen assays
Key People
Head of Machine Learning
Head of R&D Ops
Co-Head of R&D
Head of Machine Learning
Head of R&D Ops
Co-Head of R&D
News & Updates
JURA Bio demonstrated the first AI-driven generation of antibody-based scFvs that specifically target peptide-HLA complexes, expanding the landscape of druggable intracellular targets.
JURA Bio introduced variational synthesis, enabling the design and synthesis of quadrillions of protein sequences at a fraction of previous costs, representing a trillion-fold reduction in gene synthesis cost.
JURA Bio's ML-improved gene synthesis technology generated a library of 100 billion potential TCR candidates, leading to the discovery of high-value TCRs for prostate cancer and other key neoantigen targets.
Coverage of JURA Bio's VISTA platform and its impact on large-scale antibody design using AI.
Discussion on the implications of JURA Bio's advances in DNA synthesis for drug discovery.
JURA Bio recognized as a notable company in the AI drug discovery space.
JURA Bio demonstrated the first AI-driven generation of antibody-based scFvs that specifically target peptide-HLA complexes, expanding the landscape of druggable intracellular targets.
JURA Bio introduced variational synthesis, enabling the design and synthesis of quadrillions of protein sequences at a fraction of previous costs, representing a trillion-fold reduction in gene synthesis cost.
JURA Bio's ML-improved gene synthesis technology generated a library of 100 billion potential TCR candidates, leading to the discovery of high-value TCRs for prostate cancer and other key neoantigen targets.
Coverage of JURA Bio's VISTA platform and its impact on large-scale antibody design using AI.
Discussion on the implications of JURA Bio's advances in DNA synthesis for drug discovery.
JURA Bio recognized as a notable company in the AI drug discovery space.